Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atorvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 10/20 | 0.98 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.98 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.98 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.98 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | RHOC | P08134 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | THRB | P10828 | 1/20 | 0.98 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.98 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.98 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.86 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.86 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.86 |
| ▸ | PDE6D | O43924 | 3/20 | 0.76 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atorvastatin SCHEMBL537781 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL3831 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL4201645 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL13900412 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL465015 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL8257670 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL6266705 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL3056792 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL21637576 | 0.99 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL1535887 | 0.98 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103340852-A | Pharmaceutical composition containing ezetimibe and atorvastatin | BEIJING FUKANGREN BIOPHARMACEUTICAL TECHNOLOGY CO LTD | 2013-10-09 | — | — | CN | claimed |
| CN-102018708-A | Pharmaceutical composition containing amlodipine and atorvastatin magnesium | FEI LIN | 2011-04-20 | — | — | CN | claimed |
| CN-100450471-C | Soft capsule of atovastatine salts and prepn. method therefor | OUYI PHARMACEUTICAL CO LTD (CN) | 2009-01-14 | — | — | CN | claimed |
| CN-1911213-A | Soft capsule of atovastatine salts and prepn. method therefor | OUYI PHARMACEUTICAL CO LTD SHI (CN) | 2007-02-14 | — | — | CN | claimed |
| CN-1642526-A | Formulations of atorvastatin stabilized with alkali metal additions | RANBAXY LAB LTD (IN) | 2005-07-20 | — | — | CN | claimed |
| US-20030175338-A1 | Formulations of atorvastatin stabilized with alkali metal additions | RANBAXY LABORTORIES LIMITED (IN) | 2003-09-18 | — | — | US | claimed |
| WO-2003068191-A1 | FORMULATIONS OF ATORVASTATIN STABILIZED WITH ALKALI METAL ADDITIONS | RANBAXY LABORATORIES LIMITED (IN) | 2003-08-21 | — | — | WO | claimed |
| EP-1336405-A1 | Formulations of atorvastatin stabilized with alkali metal additions | RANBAXY LABORATORIES, LTD. (IN) | 2003-08-20 | — | — | EP | claimed |
| EP-4096652-A1 | USE OF STATINS TO TREAT OR PREVENT DRUG-INDUCED HEARING LOSS | The United States of America, as Represented By the Secretary, Department of Health and Human Services (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021154647-A1 | USE OF STATINS TO TREAT OR PREVENT DRUG-INDUCED HEARING LOSS | THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-08-05 | — | — | WO | disclosed |
| EP-2013188-B1 | ROSUVASTATIN ZINC SALT | EGIS GYÓGYSZERGYÁR NYILVÁNOSAN MÚKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) | 2016-09-07 | — | — | EP | disclosed |
| CN-103340852-A | Pharmaceutical composition containing ezetimibe and atorvastatin | BEIJING FUKANGREN BIOPHARMACEUTICAL TECHNOLOGY CO LTD | 2013-10-09 | — | — | CN | disclosed |
| CN-102558016-A | Novel compound with high blood fat-reducing activity and preparation method thereof | BEIJING FUKANGREN BIOPHARMACEUTICAL TECHNOLOGY CO LTD | 2012-07-11 | — | — | CN | disclosed |
| CN-102294032-A | Medicinal composition containing statins existing in zinc salt mode | — | 2011-12-28 | — | — | CN | disclosed |
| US-20030175338-A1 | Formulations of atorvastatin stabilized with alkali metal additions | RANBAXY LABORTORIES LIMITED (IN) | 2003-09-18 | — | — | US | disclosed |
| US-20030175338-A1 | Formulations of atorvastatin stabilized with alkali metal additions | RANBAXY LABORTORIES LIMITED (IN) | 2003-09-18 | — | — | US | disclosed |
| WO-2003068191-A1 | FORMULATIONS OF ATORVASTATIN STABILIZED WITH ALKALI METAL ADDITIONS | RANBAXY LABORATORIES LIMITED (IN) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068191-A1 | FORMULATIONS OF ATORVASTATIN STABILIZED WITH ALKALI METAL ADDITIONS | RANBAXY LABORATORIES LIMITED (IN) | 2003-08-21 | — | — | WO | disclosed |
| EP-1336405-A1 | Formulations of atorvastatin stabilized with alkali metal additions | RANBAXY LABORATORIES, LTD. (IN) | 2003-08-20 | — | — | EP | disclosed |
| EP-1336405-A1 | Formulations of atorvastatin stabilized with alkali metal additions | RANBAXY LABORATORIES, LTD. (IN) | 2003-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030175338-A1 | Formulations of atorvastatin stabilized with alkali metal additions | APOB, HMGCR, SLC10A1 | HMGCR 2/4885SLCO1B1 63/4885ABCB11 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.